Navigation Links
Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
Date:6/9/2008

CAMBRIDGE, Mass., June 9 /PRNewswire/ -- Radius Health ("Radius") announced today that the company has selected the first lead candidate, RAD140, from its internal nonsteroidal selective androgen receptor modulator ("SARM") discovery program, for full preclinical development as a potential therapy for the treatment of age-related muscle loss (sarcopenia) and other musculoskeletal conditions such as osteoporosis. Radius selected RAD140 from a series of promising SARMs after it demonstrated exceptional selectivity for anabolic activity in well-validated in vivo models. Radius expects to complete formal toxicology studies that will allow the company to commence human clinical trials for RAD140 in the first half of 2009.

"We are highly encouraged by data on RAD140 from our in vivo models, which demonstrate RAD140's strong potential to build new bone and muscle, with significant selectivity over prostate and other non-target tissues, excellent oral availability, and a promising safety profile," said Chris Miller, PhD, Vice President of Chemistry of Radius.

"The selection of RAD140 for pre-IND development is a significant milestone for Radius as it represents the first novel proprietary compound to emerge from the company's internal discovery program," said C. Richard Lyttle, PhD, President and CEO of Radius. "The Radius team has been extremely productive in advancing this first lead SARM candidate, and I am confident in our ability to complete preclinical studies and to initiate expected clinical trials in 2009."

About SARMs

Selective androgen receptor modulators (SARMs) are a novel class of androgen receptor ligands that bind to and selectively activate androgen receptors to promote or inhibit specific androgen action in different tissues. SARMs have the potential to substantially expand the clinical benefits of androgens, including testosterone, on muscle and bone while avoiding the unwanted side-effects, which include stimulation of the prostate. SARMs provide the opportunity to design tissue-selective, orally delivered anabolic therapies for bone loss and/or muscle wasting caused by aging, burns and trauma, cancer, chronic kidney disease, end-stage renal disease, chronic obstructive pulmonary disease (COPD), and other diseases.

About Sarcopenia

About 17% of men and 24% of women under the age of 70 suffer from age-related muscle wasting, or sarcopenia. The degenerative loss of skeletal muscle mass and strength contributes to frailty, immobility, and the loss of independence in older adults, with prevalence rising to more than 50% in men and women over 80 years of age. An estimated nine million Americans over the age of 65 suffer from sarcopenia, and there are currently no FDA-approved treatment options available. This deterioration of skeletal strength can also exacerbate other age-related conditions such as osteoarthritis and osteoporosis. Additional chronic diseases that involve loss of muscle strength with a significant impact on quality of life include cancer cachexia, chronic obstructive pulmonary disease (COPD), and chronic renal disease.

ABOUT RADIUS (http://www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $91.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

Contact:

Nick Harvey

Chief Financial Officer

(617) 551-4704


'/>"/>
SOURCE Radius Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
2. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
7. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
10. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
11. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... India , March 24, 2017 ... of the industry including definitions, classifications, applications and industry ... the international market including development history, competitive landscape analysis, ... ... Ampoules industry spread across 105 pages providing 10 company ...
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)...  Mirabilis Medical, a Seattle ... surgery, announced today CE Mark authorization for marketing ... fibroids throughout the European Union.  The company simultaneously ... US Food and Drug Administration to begin a ... United States.  The Mirabilis System combines high-speed therapeutic ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... “End Time GPS”: ... salient events will interrelate. “End Time GPS” is the creation of published author, ... expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, he ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
Breaking Medicine News(10 mins):